{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:56Z","timestamp":1791335636498,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108769","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:39:50Z","timestamp":1759131590000},"page":"108769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1157-3763","authenticated-orcid":false,"given":"Jasper H.L.T. van","family":"Genugten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7330","authenticated-orcid":false,"given":"Daniel","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Hahne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Poile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-9556","authenticated-orcid":false,"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.lungcan.2025.108769_b0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2025.108769_b0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108769_b0015","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108769_b0020","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108769_b0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108769_b0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108769_b0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108769_b0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108769_b0045","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108769_b0050","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108769_b0055","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignantpleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2025.108769_b0060","doi-asserted-by":"crossref","first-page":"1 21","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"6220","key":"10.1016\/j.lungcan.2025.108769_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2025.108769_b0070","doi-asserted-by":"crossref","unstructured":"van Genugten, Jasper, et al. \u201cThe Predictive and Prognostic Value of T-and B-cell Transcriptomic Signatures for Clinical Response to Immune Checkpoint Blockade in Pleural Mesothelioma.\u201d medRxiv (2025): 2025-05.","DOI":"10.1101\/2025.05.12.25326806"},{"key":"10.1016\/j.lungcan.2025.108769_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108769_b0080","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2025.108769_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"Damotte","year":"2019","journal-title":"J. Transl. Med."},{"issue":"D1","key":"10.1016\/j.lungcan.2025.108769_b0090","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2025.108769_b0095","series-title":"Science Translational Medicine 9.383","article-title":"The druggable genome and support for target identification and validation in drug development","author":"Finan","year":"2017"},{"key":"10.1016\/j.lungcan.2025.108769_b0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1084\/jem.20191257","article-title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice","volume":"217","author":"Badhai","year":"2020","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108769_b0105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108769_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110013","article-title":"Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells","volume":"37","author":"Matas-Rico","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108769_b0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ccell.2020.12.001","article-title":"Integrin \u03b1v\u03b26\u2013TGF\u03b2\u2013SOX4 pathway drives immune evasion in triple-negative breast cancer","volume":"39","author":"Bagati","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2025.108769_b0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI172503","article-title":"Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer","volume":"133","author":"Zhao","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"7882","key":"10.1016\/j.lungcan.2025.108769_b0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-021-03994-2","article-title":"KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements","volume":"598","author":"Zhang","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108769_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2006134","article-title":"KDM5 histone demethylases repress immune response via suppression of STING","volume":"16","author":"Wu","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.lungcan.2025.108769_b0135","doi-asserted-by":"crossref","unstructured":"Zhuang, Hongkai, Chuanzhao Zhang, and Baohua Hou. \u201cGTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer.\u201d Bioscience Reports 40.9 (2020): BSR20202150.","DOI":"10.1042\/BSR20202150"},{"issue":"7670","key":"10.1016\/j.lungcan.2025.108769_b0140","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108769_b0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hep4.1682","article-title":"Inhibition of CMTM4 sensitizes cholangiocarcinoma and Hepatocellular Carcinoma to T cell\u2013mediated antitumor immunity through PD\u2010L1","volume":"6","author":"Chui","year":"2022","journal-title":"Hepatol. Commun."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108769_b0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-14-2110","article-title":"Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma","volume":"21","author":"Otsuka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108769_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122714","article-title":"Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment","volume":"312","author":"Chu","year":"2025","journal-title":"Biomaterials"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108769_b0160","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1158\/0008-5472.CAN-20-1723","article-title":"Hedgehog signaling regulates metabolism and polarization of mammary tumor-associated macrophages","volume":"81","author":"Hinshaw","year":"2021","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108769_b0165","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s42255-024-01137-1","article-title":"Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota","volume":"6","author":"Zhang","year":"2024","journal-title":"Nature Metabolism"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108769_b0170","article-title":"The Effects of 6 Common Antidiabetic Drugs on Anti\u2010PD1 Immune Checkpoint Inhibitor in Tumor Treatment","volume":"2022","author":"Zhan","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.lungcan.2025.108769_b0175","doi-asserted-by":"crossref","unstructured":"Stagg, John, et al. \u201cAnti\u2013ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti\u2013PD-1 or anti-CD137 mAb therapy.\u201d Proceedings of the National Academy of Sciences 108.17 (2011): 7142-7147.","DOI":"10.1073\/pnas.1016569108"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108769_b0180","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/s41416-024-02835-z","article-title":"Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer","volume":"131","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"10418","key":"10.1016\/j.lungcan.2025.108769_b0185","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108769_b0190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/djad072","article-title":"Tucatinib promotes immune activation and synergizes with programmed cell death\u20131 and programmed cell death\u2013ligand 1 inhibition in HER2-positive breast cancer","volume":"115","author":"Li","year":"2023","journal-title":"JNCI: J. Nat. Cancer Inst."},{"key":"10.1016\/j.lungcan.2025.108769_b0195","doi-asserted-by":"crossref","unstructured":"Rha, Sun Young, et al. \u201cTargeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ib\/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).\u201d (2020): 3081-3081.","DOI":"10.1200\/JCO.2020.38.15_suppl.3081"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108769_b0200","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-19-1116","article-title":"Polyamine blocking therapy decreases survival of tumor-infiltrating immunosuppressive myeloid cells and enhances the antitumor efficacy of PD-1 blockade","volume":"19","author":"Alexander","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108769_b0205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0000000000000379","article-title":"Inhibition of polyamine biosynthesis using difluoromethylornithine acts as a potent immune modulator and displays therapeutic synergy with PD-1-blockade","volume":"44","author":"Dryja","year":"2021","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108769_b0210","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.1500729","article-title":"Targeting ornithine decarboxylase by \u03b1-difluoromethylornithine inhibits tumor growth by impairing myeloid-derived suppressor cells","volume":"196","author":"Ye","year":"2016","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108769_b0215","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1158\/0008-5472.CAN-18-4018","article-title":"DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer","volume":"79","author":"Travers","year":"2019","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108769_b0220","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255687","article-title":"Loss of primary cilia promotes inflammation and carcinogenesis","volume":"23","author":"Paul","year":"2022","journal-title":"EMBO Rep."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108769_b0225","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41568-018-0023-6","article-title":"Ciliary signalling in cancer","volume":"18","author":"Liu","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.lungcan.2025.108769_b0230","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1158\/1078-0432.CCR-12-0599","article-title":"Role of hedgehog signaling in malignant pleural mesothelioma","volume":"18","author":"Shi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108769_b0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable response to vismodegib in PTCH1 F1147fs mutant relapsed malignant pleural mesothelioma: implications for mesothelioma drug treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108769_b0240","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-15-0583","article-title":"Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in vivo by affecting stroma","volume":"15","author":"Meerang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108769_b0245","doi-asserted-by":"crossref","first-page":"10870","DOI":"10.3390\/ijms241310870","article-title":"GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer","volume":"24","author":"Huntington","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108769_b0250","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s43018-021-00267-9","article-title":"Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells","volume":"2","author":"Zhai","year":"2021","journal-title":"Nature Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:45:39Z","timestamp":1762490739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S0169500225006610"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108769","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108769"}}